Skip to Content
You are currently on the new version of our website. Access the old version .
MoleculesMolecules
  • Article
  • Open Access

5 March 2026

20 Pages

A Novel Wogonin Derivative Induces Apoptosis in PC-3M Cells by Targeting Mitochondrial Dysfunction and Activating the ROS-p38/MAPK Pathway

,
,
,
,
,
,
and
College of Chinese Medicinal Material, Jilin Agricultural University, 2888 Xincheng Street, Changchun 130118, China
*
Authors to whom correspondence should be addressed.

Abstract

Current cancer treatments have significant limitations. Designing TPP+-modified, mitochondrial-targeted drugs can improve anticancer efficacy. Although wogonin exhibits antitumor activity, it has drawbacks, including poor solubility and limited distribution. This study designed and synthesized 27 derivatives, including nine novel wogonin triphenylphosphine derivatives that demonstrated in vitro antitumor activity. Mito-WO-8, one of these derivatives, exhibited potent activity against PC-3M cells (IC50 = 3.19 μmol/L), demonstrating 15-fold higher potency than wogonin. Further analysis revealed that Mito-WO-8 accumulates more in mitochondria than wogonin and induces mitochondrial dysfunction, including increased reactive oxygen species, reduced membrane potential, and activation of the MPTP channel. Transcriptome and network analyses revealed that Mito-WO-8 activates the p38/MAPK pathway. Downregulation of p-MKK6 and p-p38, as well as upregulation of DDIT3 and cleaved caspase-3, were validated by Western blot (WB) and quantitative polymerase chain reaction (qPCR). Therefore, Mito-WO-8 enhances mitochondrial enrichment and induces mitochondrial damage. This process is associated with apoptosis and the activation of the ROS-p38/MAPK pathway. Additionally, the study found that Mito-WO-8 exhibits a stronger binding affinity for mitochondrial glycerol-3-phosphate dehydrogenase 2 (GPD2) than the parent compound (−9.6 kJ/mol vs. −6.6 kJ/mol), suggesting a potential interaction with GPD2. This finding establishes a foundation for further investigation into its targeted antitumor mechanism.

1. Introduction

Malignant tumors are the second leading cause of death worldwide. Traditional therapies, such as surgery, radiotherapy, and chemotherapy, significantly reduce survival rates due to bone marrow suppression and organ toxicity [1,2,3,4]. Due to their structural diversity and low toxicity, natural products have emerged as a new source for developing anticancer drugs [5]. The mitochondrial membrane potential (ΔΨm) is markedly higher in tumor cells than in normal cells, exceeding 60 mV [6]. This electrochemical gradient provides the physical basis for selective drug accumulation. Mitochondrial dysfunction, at the core of cellular energy metabolism, apoptosis regulation, and reactive oxygen species (ROS) generation, can directly induce cancer cell death [7,8,9]. Therefore, developing delivery systems that specifically target tumor mitochondria has become a key strategy for overcoming the limitations of natural products in cancer therapy [10,11,12].
Due to its strong lipophilicity, positive charge, and ΔΨm-dependent active transport capacity, triphenylphosphine (TPP+) enhances drug concentration in the mitochondrial matrix [13]. This strategy has been successfully applied to modify various natural products: Ma et al. [14] linked ginsenosides to TPP+ to form complexes that induced programmed apoptosis in tumor cells by elevating intracellular reactive oxygen species levels and disrupting mitochondrial membrane potential. Ju et al. [15] linked the natural product pentacyclic triterpene CDDO to TPP+, revealing that this derivative significantly enhanced selectivity toward tumor cells while reducing toxicity to normal mammary cells. Wogonin (WO), a flavonoid compound with antitumor activity isolated from Scutellaria baicalensis, exhibits relatively high content in the herb Figure 1). However, its pharmacological effects have been studied less extensively than those of baicalin. Research indicates that its antitumor mechanism involves multiple anticancer effects, such as inducing apoptosis, arresting the cell cycle, and inhibiting cell migration [16,17,18,19,20]. Current research on wogonin derivatives primarily focuses on enhancing water solubility and pharmacokinetic properties [21,22], while reports on their targeted antitumor capabilities are limited. Although triphenylphosphine (TPP+)-conjugated flavonoids have been developed to increase biological activity [23,24], few studies have examined their mitochondrial mechanisms of action or how they exert antitumor effects by influencing downstream pathways and proteins. Furthermore, limited research has examined how different linker lengths and functional groups affect the antitumor activity of mitochondrial-targeted TPP+ compounds sharing the same flavonoid parent structure.
Figure 1. Schematic diagram of Structure 1.
Against this backdrop, this study aims to explore a synthetic molecular design strategy that targets mitochondria. A series of compounds was designed and synthesized using wogonin as the parent structure. Through in vitro anti-proliferative activity screening, derivatives with potential activity were identified. Selected derivatives with superior activity underwent assessments of mitochondrial targeting capacity, mitochondrial function, and in vitro antitumor mechanisms. This work has theoretical significance and practical value as a reference for developing innovative drugs based on wogonin derivatives.

2. Results

2.1. Synthesis of Series A, B, and Mito-WO-TPP+

Scheme 1 outlines the synthetic route for this chemical synthesis: Using Wogonin as the core structure, compounds of Series A were synthesized by reacting it with bromic acids of varying chain lengths (n = 3–11). Meanwhile, compounds of Series B were synthesized by reacting with fatty acids of varying chain lengths (n = 3–11). Furthermore, using the compounds of Series A as intermediates, the target products—the Mito-WO-TPP+ series compounds—were subsequently synthesized Scheme 1.
Scheme 1. Synthesis route of the target compound Mito-WO-TPP+.

2.2. Cell Viability Assay

The MTT assay was used to evaluate the ability of all compounds to inhibit the proliferation of four cancer cell lines and one normal cell line. The results are presented in Table 1.
Table 1. Study on the anticancer cell inhibitory activity of WO and its derivatives in vitro.
Most Mito-WO-TPP+ compounds exhibited significant activity in PC-3M cells compared to WO (IC50 = 48.15 μmol/L) and 5-FU. Mito-WO-8 demonstrated the strongest activity (IC50 = 3.19 μmol/L)—15-fold and 18-fold higher than WO and 5-FU, respectively. Within the A series, only A4 and A8 showed marginal improvement over WO. The B series did not demonstrate superior activity overall, though B3 and B9 outperformed 5-FU. In A549 cells, most derivatives, except those in the A series, exhibited stronger activity than WO (IC50 = 77.52 μmol/L). The B series as a whole outperformed WO; Mito-WO-8 and Mito-WO-12, both from the Mito-WO-TPP+ series, had IC50 values below 10 μM. Fourteen derivatives exhibited higher activity than WO (IC50 = 60.35 μmol/L) in Bel-7402 cells. A4, A5, and A7 from the A series, and B6 from the B series, showed particularly good performance. Mito-WO-8 and -12 in the Mito-WO-TPP+ series exhibited outstanding activity (IC50 < 10 μmol/L). Only Mito-WO-7, -8, and -12 slightly outperformed 5-FU. In HGC-27 cells, 22 compounds exhibited activity superior to WO (IC50 = 49.93 μmol/L). Most compounds from Series A and B, along with all Mito-WO-TPP+ derivatives, demonstrated activity superior to that of WO. Only four of the 27 compounds tested exhibited cytotoxicity below 40 μmol/L in HEK-293 normal cells. The Mito-WO-TPP+ series exhibited low overall cytotoxicity toward normal cells. Among these compounds, Mito-WO-8 demonstrated good selectivity while inhibiting normal cells less.
The results indicate that Series A and B have limited activity against the four tumor cell lines. However, Series B demonstrates superior overall activity compared to Series A. The Mito-WO-TPP+ series exhibited significantly enhanced activity, which was not clearly correlated with carbon chain length. Mito-WO-8 demonstrated outstanding activity, particularly in PC-3M cells, with a potency over 15-fold higher than WO, while exhibiting lower cytotoxicity toward normal cells. These results confirm the critical role of the TPP+ group in enhancing activity. Consequently, Mito-WO-8 was selected for subsequent mechanistic studies with PC-3M cells.

2.3. Mito-WO-8 Accumulates in PC-3M Mitochondria

Based on the MTT activity screening results mentioned above, we found that Mito-WO-8 has the potential to inhibit PC-3M cell proliferation. Therefore, we used high-performance liquid chromatography (HPLC) to detect the peak areas of WO and Mito-WO-8 in PC-3M mitochondrial extracts at identical concentrations and exposure times. As shown in Figure 2, Mito-WO-8 exhibits a greater mitochondrial accumulation capacity than WO.
Figure 2. Aggregation and distribution of compounds WO and Mito-WO-8 in mitochondria. (A) Mito-WO-8 and WO treatment of PC-3M cells mitochondrial liquid phase diagram. (B) Peak areas of WO and Mito-WO-8 compounds in mitochondria of PC-3M cells after 7 h of drug treatment.

2.4. Mito-WO-8 Derivative Induces Mitochondrial Dysfunction in PC-3M Cells

2.4.1. Mito-WO-8 Affects Mitochondrial Membrane Potential Decline

The results are shown in Figure 3. Under fluorescence microscopy, the control group exhibited a high membrane potential, with JC-1 forming polymers and emitting red fluorescence. However, compared to the control group, most cells in the treated group exhibited monomeric JC-1 and emitted green fluorescence. These results indicate that the drug treatment significantly reduced the mitochondrial membrane potential of PC-3M cells, suggesting mitochondrial damage.
Figure 3. Effect of Mito-WO-8 on Mitochondrial Membrane Potential of PC-3M Cells. (A) Confocal imaging of different concentrations of Mito-WO-8 in PC-3M cells. Cells without drug treatment were used as a control group. (B) Red fluorescence represents healthy mitochondria. (C) Green fluorescence indicates that mitochondria are damaged. The values are means ± SD from three independent experiments (n = 3). ns: insignificant. **** p < 0.0001 compared to the control group. Scale bar: 100 µm. Group comparisons were analyzed using one-way analysis of variance (ANOVA) followed by Bonferroni’s multiple-comparison test.

2.4.2. Mito-WO-8 Inhibits MPTP Permeability

The transient opening of the mitochondrial permeability transition pore (mPTP) is essential for maintaining mitochondrial homeostasis. However, prolonged mPTP opening disrupts the organelle’s osmotic balance, leading to outer membrane rupture in severe cases. Ultimately, this results in the release of mitochondrial contents into the cytoplasm, inducing apoptosis. Figure 4 shows the experimental results. In the blank control group, strong green fluorescence exhibited distinct rod-like or filamentous structures. In the Mito-WO-8 treatment group, increasing drug concentrations led to progressively weaker fluorescence signals and significant morphological changes; fluorescence signals gradually weakened, and morphological changes became more pronounced. The filamentous structures, which were originally clearly visible, gradually became circular. Ultimately, the fluorescence signals diffused and nearly disappeared completely. This indicates that mitochondrial structural integrity was progressively disrupted.
Figure 4. Effect of Mito-WO-8 on the degree of mitochondrial MPTP pore opening in PC-3M cells. (A) Measurement of mitochondrial permeability transition pore opening with Calcein AM and CoCl2. (B) Quantification of the degree of opening of MPTP when cells were treated with different drug concentrations, with the control group being the no-drug group. The values are means ± SD from three independent experiments (n = 3). **** p < 0.0001. Scale bar: 50 µm compared to the control group. Group comparisons were analyzed using one-way analysis of variance (ANOVA) followed by Bonferroni’s multiple-comparison test.

2.5. Mito-WO-8 Promotes ROS Generation

ROS was used as a positive control to detect ROS levels in PC-3M cells via flow cytometry. As shown in Figure 5, compared with the control group, a significant increase in ROS levels was observed in the Mito-WO-8-treated group. This upward trend showed a positive correlation with increasing drug concentrations.
Figure 5. Effect of Mito-WO-8 on intracellular ROS levels in PC-3M cells. (A) The effect of Mito-WO-8 on ROS content in PC-3M cells, with ROS up as the positive control group. (B) Intracellular ROS levels after drug treatment. The values are means ± SD from three independent experiments (n = 3). * p < 0.05, ** p < 0.01, *** p < 0.001 compared to the control group. Group comparisons were analyzed using one-way analysis of variance (ANOVA) followed by Bonferroni’s multiple-comparison test.

2.6. Mito-WO-8 Induces Apoptosis in PC-3M Cells

Figure 6A shows that cells in the control group have intact, uniform morphology and pale-blue fluorescence. These cells show no signs of apoptosis. In the group treated with a low concentration of Mito-WO-8 (1.25 μmol/L), fewer bright-blue fluorescent spots were observed with reduced intensity, though the number of cells remained relatively high. At 2.5 μmol/L, most cells exhibited bright-blue fluorescence, indicating nuclear condensation and margination, resulting in increased staining intensity. At 5 μmol/L, cell numbers decreased significantly, and irregular bright-blue fluorescence appeared. Nuclear chromatin showed marked condensation, concentrating on one side of the nuclear envelope and adopting a crescent shape. This indicates entry into the apoptotic phase.
Figure 6. The effect of Mito-WO-8 on apoptosis of PC-3M cells. (A) The DAPI staining method was used to detect the effect of Mito-WO-8 on apoptosis of PC-3M cells; (B) Percentage of live versus dead cells after treatment with different drug concentrations; (C) The schematic diagram of cell apoptosis obtained through flow cytometry analysis. The values are means ± SD from three independent experiments (n = 3). ** p < 0.01, *** p < 0.001 compared to the control group. Group comparisons were analyzed using one-way analysis of variance (ANOVA) followed by Bonferroni’s multiple-comparison test.
Figure 6B,C show that the apoptosis rate of PC-3M cells increased significantly with increasing drug concentrations. While the apoptosis rate was 3.94% in the control group, it increased to 17.47%, 28.53%, and 37.67% with increasing drug concentrations. Therefore, it can be inferred that Mito-Wo-8 can induce apoptosis in PC-3M cells.

2.7. Integrated Transcriptomic and Network Pharmacology Analysis of Mito-WO-8’s Signal Pathways and Potential Targets Against PC-3M

A transcriptomic analysis was conducted to investigate the potential mechanisms of Mito-WO-8’s anti-PC-3M activity. The results are shown in Figure 7A. The volcano plot depicts the differentially expressed genes (DEGs) and differentially expressed proteins (DEPs) in the control and Mito-WO-8 groups. (A). Each point represents a gene: red indicates upregulation, green indicates downregulation, and black indicates no differential expression. The analysis revealed that, compared to the blank group, 51 genes were upregulated and 287 were downregulated following administration. Their biological activities were explored through GO and KEGG analyses.
Figure 7. Transcriptome analysis. (A) Volcanic map of differential gene expression (The dashed lines indicate thresholds for gene expression changes, where blue represents downregulation and red represents upregulation); (B) KEGG pathway enrichment analysis; (C) GO analysis. The experimental results were repeated more than three times (Green represents biological processes, blue represents cellular components, and orange represents molecular functions). The values are means ± SD from three independent experiments (n = 3).
Enrichment analysis via the GO database revealed significant enrichment at a corrected p-value (p-adj) of <0.05. The top 20 most significant terms were analyzed. Compared to the blank group, the differentially expressed genes after administration were primarily enriched in mitosis, nuclear chromosome segregation, cell division, and organelle fission, as shown in Figure 7C.
We performed a KEGG pathway enrichment analysis of the genes in the gene set using R scripts (3.14.0). The results were visualized via bubble plots, and significant enrichment was identified when p-adj < 0.05. The top 20 significantly enriched KEGG pathways were selected, including the MAPK, PI3K-AKT, Rap1, oxytocin, and p53 signaling pathways. The MAPK pathway showed significant enrichment among these pathways. The MAPK pathway is pivotal in cancer cells and is closely interlinked with other pathways, as illustrated in Figure 7B. In summary, Mito-WO-8 may exert its antitumor effects by mediating the MAPK pathway in PC-3M cells.
We obtained differentially expressed genes from the TCGA database for 35,067 human prostate cancer cells and normal prostate cells. Based on screening criteria of |log2FC| > 1.5 and p < 0.05, 1096 differentially expressed genes were identified. This dataset is defined as Dataset 1. A total of 1137 mitochondrial genes were obtained from the Mito Carta 3.0 database and constitute Dataset 2. An overlap analysis of Datasets 1 and 2 using Venn diagrams identified 1109 genes that were differentially expressed in both datasets, as shown in Figure 8A.
Figure 8. Transcriptome-integrated network pharmacology analysis of key targets. (A) VEEN plot analysis of differentially expressed genes overlapping with mitochondria (B) Transcriptome-integrated network pharmacology analysis of differentially expressed genes associated with mitochondria.
After crossing the 1109 differentially regulated genes predicted by network pharmacology with the 340 differentially expressed genes obtained from transcriptome sequencing, six genes associated with mitochondria were identified (Figure 8B). The associated genes were GPD2, POLQ, DMGDH, C2orf69, DHRS2, and ARG2. GPD2, also known as mitochondrial FAD-coupled glycerol-3-phosphate dehydrogenase, is a flavin-coupled glycerol-3-phosphate ubiquinone oxidoreductase. GPD2 is a mitochondrial enzyme located on the outer surface of the inner mitochondrial membrane and influences mitochondrial membrane potential and reactive oxygen species (ROS) production [25]. Studies have documented the association between GPD2 and cancer, showing that tumor proliferation is significantly reduced following treatment with GPD2 activity inhibitors [26]. Molecular docking prediction was performed with wogonin and Mito-WO-8 against GPD2 to investigate their function. Figure 9 showed that Mito-WO-8 exhibited a higher binding energy to GPD2 (−9.6 kJ/mol) than wogonin (−6.6 kJ/mol).
Figure 9. WO and Mito-WO-8 Docking Diagram with GPD2. (The blue and purple regions illustrate the interactions between small molecules and proteins).

2.8. Validation of Related Genes

2.8.1. RT-qPCR Validation

The results are shown in Figure 10. Compared to the control group, the expression of the GPD2 and MKK6 proteins was significantly suppressed after Mito-WO-8 treatment (p < 0.01). DDIT3 protein expression increased significantly after Mito-WO-8 treatment (p < 0.001). However, there was no significant difference in P38 protein expression compared to the control group.
Figure 10. RT-qPCR detection of the effect of derivative Mito-WO-8 on GPD2 and MAPK pathway-related proteins. The values are means ± SD from three independent experiments (n = 3). ns: insignificant. ** p < 0.01, *** p < 0.001 compared to the control group. Group comparisons were analyzed using one-way analysis of variance (ANOVA) followed by Bonferroni’s multiple-comparison test.

2.8.2. Western Blot Validation

To confirm that the derivative Mito-WO-8 induces apoptosis in PC-3M cells by activating the MAPK pathway, a Western blot analysis was performed to detect the relevant proteins. Figure 11 showed that, compared with the blank control group, GPD2 levels decreased significantly in cells treated with the derivative Mito-WO-8 at increasing concentrations (p < 0.001). Key proteins in the MAPK pathway (P-MKK6 and P-p38) also decreased significantly with increasing concentrations (p < 0.001). Meanwhile, Figure 12 showed that, DDIT3 and cleaved caspase-3 protein levels gradually increased with increasing Mito-WO-8 concentrations (p < 0.01). These results confirm that Mito-WO-8 can induce apoptosis and that this process exhibits a clear dose-dependent relationship.
Figure 11. Western blot analysis of the effect of derivative Mito-WO-8 on GPD2 and MAPK pathway-related proteins. The values are means ± SD from three independent experiments (n = 3). ns: insignificant. * p < 0.05, ** p < 0.01, *** p < 0.001 compared to the control group. Group comparisons were analyzed using one-way analysis of variance (ANOVA) followed by Bonferroni’s multiple-comparison test.
Figure 12. Western blot analysis of the effect of compound Mito-WO-8 on apoptosis-related Cl-caspase3 proteins. The values are means ± SD from three independent experiments (n = 3). ** p < 0.01, *** p < 0.001 compared to the control group. Group comparisons were analyzed using one-way analysis of variance (ANOVA) followed by Bonferroni’s multiple-comparison test.

3. Discussion

This study systematically optimized the esterification reaction systems for both Series A and Series B compounds. For both Series A and Series B, the optimal conditions were achieved using dichloromethane as the solvent and reacting at room temperature for 1.5~2 h, yielding conversion rates of 75–80%. Feed ratios were adjusted based on the carbon chain length of the acid: short-chain compounds (C4–C6) exhibited optimal results with a 1:2 dichloromethane-to-bromic acid ratio; medium-to-long-chain compounds (C7–C12) achieved 80% conversion at a 1:1.5 ratio. Appropriately increasing the reactant ratio promotes forward progression of the reversible esterification reaction. During the reaction between Series A compounds and the titanium triphosphate cation (TPP+), the initial 1:5 ratio proved inefficient in acetone–nitrile media due to trace moisture. Switching to anhydrous acetonitrile markedly improved conversion rates, though residual titanium triphosphate compromised product purity. The final optimized conditions were established as a 1:3 feed ratio at 85 °C in anhydrous acetonitrile. This approach achieves complete conversion of raw materials while facilitating product separation and purification.
As a lipophilic cation, TPP+ can deliver drugs specifically to mitochondria. Coupling TPP with drugs promotes mitochondrial uptake, ensuring efficacy while minimizing damage to normal tissues and reducing side effects of targeted drugs [27,28,29]. The mitochondrial enrichment properties of Mito-WO-8 and WO, identified through MTT assays, were validated by high-performance liquid chromatography (HPLC). Results demonstrated that Mito-WO-8 accumulated at higher levels within mitochondria than its parent compound WO.
Reduced mitochondrial membrane potential and the opening of the mitochondrial permeability transition pore (mPTP) confirm mitochondrial dysfunction. This is accompanied by elevated levels of reactive oxygen species (ROS). Decreases in mitochondrial membrane potential and ROS bursts, which are induced by mitochondrial dysfunction, play a key role in apoptosis [30]. Glycerol-3-phosphate dehydrogenase 2 (GPD2) is a key enzyme in the mitochondrial outer membrane and a core component of the glycerol-3-phosphate transport system (G3PS) [31]. In tumor cells, downregulation of GPD2 leads to mitochondrial membrane potential depolarization and respiratory chain dysfunction [32], thereby activating the apoptosis pathway. Collectively, molecular docking, real-time quantitative PCR, and Western blot analysis confirm the potential interaction between Mito-WO-8 and glucose-6-phosphate dehydrogenase 2 (GPD2). Further studies are needed to elucidate the underlying mechanism of action. The p38 MAPK signaling pathway is a key regulator of pro-inflammatory cytokine biosynthesis at the transcriptional and translational levels. It is activated by oxidative stress and inflammatory cytokines [33]. In non-small cell lung cancer, p38 inhibitors enhance chemotherapy sensitivity significantly by activating mitochondrial-dependent apoptosis pathways (e.g., Bax/Bcl-2 imbalance and caspase-3 activation) [25]. DAPI staining revealed uneven bright-blue fluorescence in cells of the Mito-WO-8-treated group. Further analysis showed that 37.67% of these cells were apoptotic (p < 0.001). To determine whether Mito-WO-8 induces apoptosis in PC-3M cells, RT-qPCR analysis revealed significantly suppressed MKK6 protein expression (p > 0.01) and markedly increased DDIT3 protein expression (p < 0.001) following Mito-WO-8 treatment. However, there was no significant difference in P38 protein expression compared to the control group. Western blot analysis of cleaved caspase-3 (Cl-caspase3) and critical genes in the MAPK pathway revealed that Cl-caspase3 protein levels significantly increased with rising drug concentrations (p < 0.001), while p-MKK6 and p-P38 decreased significantly (p < 0.001), and DDIT3 increased (p < 0.01). These findings corroborate the MAPK pathway identified in the KEGG pathway enrichment analysis of the transcriptome, as well as the Western blot (WB) results showing downregulation of p-P38 and p-MKK6 expression.

4. Materials and Methods

4.1. Chemistry

4.1.1. Generic Protocols

The natural extract wogonin was purchased from Xi’an Xintianyu Co., Ltd. (Xi’an, China), with a purity of 98%. All other raw materials and solvents were of analytical grade and required no further purification (Xilong Chemical, Guangzhou, China). Silica gel plate GF254 was purchased from Qingdao Ocean Chemical Co., Ltd. (Qingdao, China) for monitoring the reaction progress via thin-layer chromatography (TLC). 1H NMR and 13C NMR spectra of all compounds were recorded using a Varian InfinityPlus-300 (Palo Alto, CA, USA). CD Cl3 served as the solvent (Guoyao, Beijing, China). Coupling constants (J) are expressed in hertz (Hz).

4.1.2. Methods for Synthesizing the Target Compound Mito-WO-TPP+

WO (0.21 mmol, 60.0 mg), EDCI (0.21 mmol, 40.46 mg), DMAP (0.21 mmol, 25.66 mg), and various bromic acids (n = 3–11) (0.32–0.42 mmol, 70.14 mg/76.03 mg/81.91 mg/66.9 mg/71.38 mg/75.87 mg/80.35 mg/84.84 mg/89.32 mg) were added to 20 mL of dichloromethane and reacted at room temperature for 1.5–2 h. TLC monitoring confirmed reaction completion, yielding a yellow, clear solution. Water and ethyl acetate were added, and the mixture was extracted five times. The organic layer was collected, the solvent was removed, and a powder was obtained. The crude product was purified by silica gel column chromatography (300–400 mesh, petroleum ether/acetone = 20:1–5:1) to afford the A-series compounds (A1–A9). Compounds A1–A9 correspond to n = 3–11, respectively.
WO (0.14 mmol, 40.0 mg), EDCI (0.14 mmol, 26.84 mg), DMAP (0.14 mmol, 17.19 mg), and various fatty acids (n = 3–11) (0.21–0.28 mmol, 24.65 mg/28.58 mg/32.5 mg/27.32 mg/30.26 mg/33.21 mg/36.15 mg/39.09 mg/42.04 mg) were added to 15 mL of dichloromethane and reacted at room temperature for 1.5–2 h. Monitoring by thin-layer chromatography confirmed reaction completion, yielding a yellow transparent solution. The following steps were then conducted: Add water and ethyl acetate, then extract the mixture five times. Collect the organic layers, remove the solvent, and obtain a powdery crude product. Purify using silica gel column chromatography (300–400 mesh, petroleum ether/acetone = 20:1–5:1) to afford the B-series compounds (B1–B9). Compounds B1–B9 correspond to n = 3–11, respectively.
Add intermediate A series (0.069 mmol) and TPP+ (0.208 mmol) sequentially to a 50 mL reaction flask. Reflux the mixture in 30 mL of anhydrous acetonitrile at 85 °C for 60 h. Monitor the reaction by thin-layer chromatography (TLC) until complete conversion is confirmed. After recovering the reagents, the reaction products were purified by silica gel column chromatography (300–400 mesh, chloroform: methanol = 12:1), yielding the Mito-WO-TPP+ series compounds. The synthesis processes of compounds Mito-WO-4 to Mito-WO-12 correspond to compounds A1 to A9 (n = 3–11), respectively.
Methods for Determining Purity: Agilent ZORBAX SB-C18 (4.6 mm × 250 mm × 5 µm) (Agilent Technologies, CA, USA) column, methanol-0.1% formic acid water (80:20), flow rate 1.0 mL/min, column temperature 25 °C, detection wavelength 270 nm. All compounds have a purity greater than 95%. Spectral data for all target compounds are provided below:
  • 7-(4-Bromobutyl)-Wogonin-Triphenylphosphine Splice (Mito-WO-4), Yield 25.5%. Properties: light yellow viscous substance. 1H NMR (300 MHz, CDCL3) δppm: 12.36 (1H, s, H-5), 7.93–7.92 (m, 2H, H-2′, 6′), 7.90–7.85 (m, 6H, p h-b, f), 7.78–7.68 (m, 9H, p h-c, d, e), 7.57–7.53 (m, 3H, H-4′, H-5′, H-3′), 6.73 (1H, s, H-6), 6.54 (1H, s, H-3), 4.20 (2H, m, H-4″), 3.95 (s, 3H, -OCH3), 3.34 (2H, t, J = 6.6 Hz, H-2″), 2.07 (s, 2H, H-3″). 13C NMR (75 MHz, CDCL3) δppm: 182.42(C-4), 170.34 (C-1″), 163.90 (C-2), 155.94 (C-5), 149.24 (C-9), 148.76 (C-7), 134.65 (p h-C, 3C-d), 133.37 (d, p = 10 Hz, p h-C, 6C-b, f), 131.96 (C-8), 131.89 (C-4′), 130.33 (C-1′), 130.15 (d, p = 12.5 Hz, p h-C, 6C-c, e), 128.83 (C-5′, C-3′), 125.85 (C-2′, C-6′), 118.13 (d, p = 85 Hz, p h-C, 3C-a), 109.01 (C-3), 105.41 (C-10), 105.35 (C-6), 61.84 (8-OCH3), 32.90 (C-2″), 21.52 (C-4″), 20.83 (C-3″). HRMS (ESI) m/z: 615.1913 (C38H32O6P+ [M − Br]+ calcd. for 615.1931).
  • 7-(5-Bromopentyl)-Wogonin-Triphenylphosphine Splice (Mito-WO-5), Yield 31%. Properties: light yellow viscous substance. 1H NMR (300 MHz, CDCL3) δppm: 12.36 (1H, s, H-5), 7.91–7.89 (m, 2H, H-2′, 6′), 7.86–7.82 (m, 6H, p h-b, f), 7.71–7.65 (m, 9H, p h-c, d, e), 7.57–7.54 (m, 3H, H-4′, H-5′, H-3′), 6.74 (1H, s, H-6), 6.38 (1H, s, H-3), 3.99 (s, 3H, -OCH3), 3.87 (2H, m, H-5″), 2.79 (2H, t, J = 6.0 Hz, H-2″), 2.19–2.17 (2H, m, H-3″), 1.86–1.84 (2H, m, H-4″). 13C NMR (75 MHz, CDCL3) δppm: 182.49 (C-4), 170.20 (C-1″), 163.97 (C-2), 155.88 (C-5), 149.31 (C-9), 148.81 (C-7), 134.70 (p h-C, 3C-d), 133.31 (d, p = 10 Hz, p h-C, 6C-b, f), 132.08 (C-8), 131.99 (C-4′), 130.40 (C-1′), 130.21 (d, p = 12.5 Hz, p h-C, 6C-c, e), 128.91(C-5′, C-3′), 125.90(C-2′, C-6′), 118.34(d, p = 85.8 Hz, p h-C, 3C-a), 109.00 (C-3), 105.56 (C-10), 104.87 (C-6), 61.56 (8-OCH3), 32.67 (C-2″), 24.87 (C-4″), 22.44 (C-5″), 21.39 (C-3″). HRMS (ESI) m/z: 629.2105 (C39H34O6P+ [M − Br]+ calcd. for 629.2088).
  • 7-(6-Bromohexyl)-Wogonin-Triphenylphosphine Splice (Mito-WO-6), Yield 28.9%. Properties: light yellow viscous substance. 1H NMR (300 MHz, CDCL3) δppm: 12.37 (1H, s, H-5), 7.94–7.91 (m, 2H, H-2′, 6′), 7.89–7.82 (m, 6H, p h-b, f), 7.76–7.66 (m, 9H, p h-c, d, e), 7.58–7.54 (m, 3H, H-4′, H-5′, H-3′), 6.74 (1H, s, H-6), 6.47 (1H, s, H-3), 3.92 (3H, s, 8-OCH3), 3.86 (2H, m, H-6″), 2.65 (t, J = 6.6 Hz, 2H, H-2″), 2.10 (2H, s, H-5″), 1.79–1.74 (4H, m, H-4″, H-3″). 13C NMR (75 MHz, CDCL3) δppm: 183.39 (C-4), 171.35 (C-1″), 164.86 (C-2), 156.79 (C-5), 150.22 (C-9), 149.82 (C-7), 135.52 (p h-C, 3C-d), 134.17 (d, p = 10 Hz, p h-C, 6C-b, f), 133.01 (C-8), 132.80 (C-4′), 131.31 (C-1′), 130.08(d, p = 12.5 Hz, p h-C, 6C-c, e), 129.77 (C-5′, C-3′), 126.80 (C-2′, C-6′), 119.28 (d, p = 85 Hz, p h-C, 3C-a), 109.86 (C-3), 106.43 (C-10), 105.80 (C-6), 62.46 (8-OCH3), 33.91 (C-2″), 30.17 (C-4″), 24.65 (C-5″), 23.35 (C-3″), 22.92 (C-6″). HRMS (ESI) m/z: 643.2256 (C40H36O6P+ [M − Br]+ calcd. for 643.2244).
  • 7-(7-Bromoheptyl)-Wogonin-Triphenylphosphine Splice (Mito-WO-7), Yield 33.7%. Properties: light yellow viscous substance. 1H NMR (300 MHz, CDCL3) δppm: 12.37 (1H, s, H-5), 7.93–7.90 (m, 2H, H-2′, 6′), 7.88–7.81 (m, 6H, p h-b, f), 7.77–7.68 (m, 9H, p h-c, d, e), 7.56 (m, 3H, H-4′, H-5′, H-3′), 6.74 (1H, s, H-6), 6.49 (1H, s, H-3), 3.92 (3H, s, 8-OCH3), 3.84 (2H, d, J = 15.3 Hz, H-7″), 2.62 (t, J = 7.2 Hz, 2H, H-2″), 2.08–2.01 (2H, m, H-3″), 1.75–1.70 (4H, m, H-6″, H-5″), 1.52–1.47 (2H, m, H-4″). 13C NMR (75 MHz, CDCL3) δppm: 182.96 (C-4), 171.04 (C-1″), 164.43 (C-2), 156.38 (C-5), 149.81 (C-9), 149.45 (C-7), 135.09 (p h-C, 3C-d), 133.74 (d, p = 10 Hz, p h-C, 6C-b, f), 132.61 (C-8), 132.39 (C-4′), 130.89 (C-1′), 130.64 (d, p = 12.5 Hz, p h-C, 6C-c, e), 129.35 (C-5′, C-3′), 126.37 (C-2′, C-6′), 118.89 (d, p = 85 Hz, p h-C, 3C-a), 109.43 (C-3), 105.95 (C-10), 105.89 (C-6), 61.96 (8-OCH3), 33.48 (C-2″), 29.66 (C-6″), 28.28 (C-4″), 28.10 (C-5″), 24.26 (C-3″), 22.20 (C-7″). HRMS (ESI) m/z: 657.2386 (C41H38O6P+ [M − Br]+ calcd. for 657.2401).
  • 7-(8-Bromooctyl)-Wogonin-Triphenylphosphine Splice (Mito-WO-8), Yield 31.8%. Properties: light yellow viscous substance. 1H NMR (300 MHz, CDCL3) δppm: 12.37 (1H, s, H-5), 7.93–7.91 (m, 2H, H-2′, 6′), 7.86–7.80 (m, 6H, p h-b, f), 7.77–7.68 (m, 9H, p h-c, d, e), 7.58–7.54 (m, 3H, H-4′, H-5′, H-3′), 6.74 (1H, s, H-6), 6.49 (1H, s, H-3), 3.92 (3H, s, 8-OCH3), 3.78 (2H, m, H-8″), 2.59 (t, J = 7.2 Hz, 2H, H-2″), 2.12 (2H, m, H-3″), 1.73–1.62 (6H, m, H-7″, H-6″, H-5″), 1.38 (2H, s, H-4″). 13C NMR (75 MHz, CDCL3) δppm: 182.57 (C-4), 170.68 (C-1″), 164.05 (C-2), 155.96 (C-5), 149.41 (C-9), 149.07 (C-7),134.70 (p h-C, 3C-d), 133.29(d, p = 10 Hz, p h-C, 6C-b, f), 132.23 (C-8), 131.98 (C-4′), 130.48 (C-1′), 130.23 (d, p = 12.5 Hz, p h-C, 6C-c, e), 128.95 (C-5′, C-3′), 125.98 (C-2′, C-6′), 118.49 (d, p = 85 Hz, p h-C, 3C-a), 109.02 (C-3), 105.54 (C-10), 105.48 (C-6), 61.56 (8-OCH3), 33.48 (C-2″), 29.66 (C-7″), 28.28 (C-4″), 28.10 (C-5″), 24.26 (C-3″), 22.20 (C-8″), 21.87 (C-6″). HRMS (ESI) m/z: 671.2569 (C42H40O6P+ [M − Br]+ calcd. for 671.2557).
  • 7-(9-Bromononyl)-Wogonin-Triphenylphosphine Splice (Mito-WO-9), Yield 38%. Properties: light yellow viscous substance. 1H NMR (300 MHz, CDCL3) δppm: 12.38 (1H, s, H-5), 7.94–7.91 (m, 2H, H-2′, 6′), 7.89–7.84 (m, 6H, p h-b, f), 7.79–7.67 (m, 9H, p h-c, d, e), 7.58–7.54 (m, 3H, H-4′, H-5′, H-3′), 6.74 (1H, s, H-6), 6.51 (1H, s, H-3), 3.94 (3H, s, 8-OCH3), 3.83 (2H, m, H-9″), 2.60 (2H,t, J = 6.9 Hz, H-2″), 1.73–1.68 (6H, m, H-3″, H-8″, H-7″), 1.36–1.31 (m, 6H, H-6″, H-4″, H-5″). 13C NMR (75 MHz, CDCL3) δppm: 183.00 (C-4), 171.16 (C-1″), 164.45 (C-2), 156.41 (C-5), 149.85 (C-9), 149.50 (C-7), 135.12 (p h-C, 3C-d), 133.76 (d, p = 10 Hz, p h-C, 6C-b, f), 132.66 (C-8), 132.39 (C-4′), 130.92 (C-1′), 130.65 (d, p = 12.5 Hz, p h-C, 6C-c, e), 129.38 (C-5′, C-3′), 126.40 (C-2′, C-6′), 118.95 (d, p = 85 Hz, p h-C, 3C-a), 109.46 (C-3), 106.03(C-10), 105.97 (C-6), 61.92 (8-OCH3), 33.99 (C-2″), 30.26 (C-8″), 29.72 (C-6″), 28.96 (C-4″), 28.81 (C-5″), 24.80 (C-3″), 23.13 (C-9″), 22.71 (C-7″). HRMS (ESI) m/z: 685.2733 (C43H42O6P+ [M − Br]+ calcd. for 685.2714).
  • 7-(10-Bromodecyl)-Wogonin-Triphenylphosphine Splice (Mito-WO-10), Yield 39.3%. Properties: light yellow viscous substance. 1H NMR (300 MHz, CDCL3) δppm: 12.37 (1H, s, H-5), 7.94–7.91 (m, 2H, H-2′, 6′), 7.87–7.82 (m, 6H, p h-b, f), 7.78–7.68 (m, 9H, p h-c, d, e), 7.58–7.54 (m, 3H, H-4′, H-5′, H-3′), 6.74 (1H, s, H-6), 6.51 (1H, s, H-3), 3.94 (3H, s, 8-OCH3), 3.76 (2H, m, H-10″), 2.61 (t, J = 7.5 Hz, 2H, H-2″), 1.76–1.71 (m, 6H, H-3″, H-9″, H-8″), 1.38–1.24 (m, 8H, H-7″, H-4″, H-5″, H-6″). 13C NMR (75 MHz, CDCL3) δppm: 182.98 (C-4), 171.15 (C-1″), 164.45 (C-2), 156.36 (C-5), 149.83 (C-9), 149.49 (C-7), 135.10 (p h-C, 3C-d), 133.69 (d, p = 10 Hz, p h-C, 6C-b, f), 132.66 (C-8), 132.38 (C-4′), 130.90 (C-1′), 130.64 (d, p = 12.3 Hz, p h-C, 6C-c, e), 129.35 (C-5′, C-3′), 126.37 (C-2′, C-6′), 118.91 (d, p = 85 Hz, p h-C, 3C-a), 109.44 (C-3), 105.95 (C-10), 105.89 (C-6), 61.87 (8-OCH3), 34.49 (C-2″), 31.00 (C-9″), 29.90 (C-5″), 28.94 (C-7″), 28.51 (C-4″), 24.47 (C-6″), 22.75 (C-3″), 22.27 (C-10″), 22.22 (C-8″). HRMS (ESI) m/z: 699.2883 (C44H44O6P+ [M − Br]+ calcd. for 699.2870).
  • 7-(11-Bromoundecyl)-Wogonin-Triphenylphosphine Splice (Mito-WO-11), Yield 41.6%. Properties: light yellow viscous substance. 1H NMR (300 MHz, CDCL3) δppm: 12.38 (1H, s, H-5), 7.94–7.92 (m, 2H, H-2′, 6′), 7.88–7.80 (m, 6H, p h-b, f), 7.76–7.66 (m, 9H, p h-c, d, e), 7.58–7.54 (m, 3H, H-4′, H-5′, H-3′), 6.74 (1H, s, H-6), 6.52 (1H, s, H-3), 3.90 (3H, s, 8-OCH3), 3.78 (2H, m, H-11″), 2.61 (t, J = 7.5 Hz, 2H, H-2″), 1.78–1.71 (6H, m, H-3″, H-10″, H-9″), 1.40–1.25 (10H, m, H-8″, H-4″, H-5″, H-7″, H-6″). 13C NMR (75 MHz, CDCL3) δppm: 183.43 (C-4), 171.59 (C-1″), 164.89 (C-2), 156.86 (C-5), 150.29 (C-9), 149.95 (C-7), 135.52 (p h-C, 3C-d), 134.18 (d, p = 10 Hz, p h-C, 6C-b, f), 133.11 (C-8), 132.81 (C-4′), 131.39 (C-1′), 130.08 (d, p = 12.3 Hz, p h-C, 6C-c, e), 129.80 (C-5′, C-3′), 126.83 (C-2′, C-6′), 119.42 (d, p = 85 Hz, p h-C, 3C-a), 109.90 (C-3), 106.42 (C-10), 106.36 (C-6), 62.35 (8-OCH3), 34.49 (C-2″), 31.00 (C-10″), 29.90 (C-5″), 28.94 (C-8″), 28.87 (C-7″),28.51 (C-4″), 24.47 (C-6″), 22.75 (C-3″), 22.27 (C-11″), 22.22 (C-9″). HRMS (ESI) m/z: 713.3015 (C45H46O6P+ [M − Br]+ calcd. for 713.3027).
  • 7-(12-Bromododecyl)-Wogonin-Triphenylphosphine Splice (Mito-WO-12), Yield 44.6%. Properties: light yellow viscous substance. 1H NMR (300 MHz, CDCL3) δppm: 12.38 (1H, s, H-5), 7.94–7.92 (m, 2H, H-2′, 6′), 7.88–7.81 (m, 6H, p h-b, f), 7.79–7.68 (m, 9H, p h-c, d, e), 7.58–7.54 (m, 3H, H-4′, H-5′, H-3′), 6.74 (1H, s, H-6), 6.52(1H, s, H-3), 3.94 (3H, s, 8-OCH3), 3.82 (2H, m, H-12″), 2.62 (t, J = 7.2 Hz, 2H, H-2″), 1.79–1.74 (6H, m, H-3″, H-11″, H-10″), 1.41–1.22 (12H, m, H-9″, H-4″, H-5″, H-8″, H-6″, H-7″). 13C NMR (75 MHz, CDCL3) δppm: 182.51 (C-4), 170.68 (C-1″), 163.97 (C-2), 155.95 (C-5), 149.38 (C-9), 149.06 (C-7), 134.62 (p h-C, 3C-d), 133.29 (d, p = 10 Hz, p h-C, 6C-b, f), 132.21 (C-8), 131.92 (C-4′), 130.47 (C-1′), 130.18 (d, p = 12.3 Hz, p h-C, 6C-c, e), 128.90 (C-5′, C-3′), 125.91 (C-2′, C-6′), 118.48 (d, p = 85 Hz, p h-C, 3C-a), 108.98 (C-3), 105.51 (C-10), 105.45 (C-6), 61.44 (8-OCH3), 33.61 (C-2″), 30.11 (C-11″), 29.90 (C-6″), 28.94 (C-5″),28.87 (C-9″), 28.71 (C-8″), 28.51 (C-4″), 24.47 (C-7″), 22.75 (C-3″), 22.27 (C-12″), 22.22 (C-10″). HRMS (ESI) m/z: 727.3195 (C46H48O6P+ [M − Br]+ calcd. for 727.3183).

4.2. In Vitro Antitumor Mechanism Studies

4.2.1. Reagents and Instruments

The chemical reagents used in this study are as follows: 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyltetrazolium bromide (MTT) (Solarbio, Beijing, China); 5-fluorouracil (5-FU) (Solarbio, Beijing, China); dimethyl sulfoxide (DMSO) (Solarbio, Beijing, China). Annexin V-FITC/PI (propidium iodide) apoptosis detection kits were employed (Solarbio, Beijing, China). Mitochondrial Isolation Kit, JC-1, ROS, and Calcein AM kits were purchased from Shanghai Biyuntian Technology Co., Ltd. (Shanghai, China). A flow cytometer was purchased from BD (Franklin Lakes, NJ, USA) and an inverted fluorescence microscope from Leica (ZQQ, DE).

4.2.2. Cell Culture

Human prostate cancer cells (PC-3M) were obtained from Shanghai Zeyi Biotechnology Co., Ltd. (Shanghai, China) Human non-small cell lung cancer cells (A549), human hepatocellular carcinoma cells (BEL-7402), and human embryonic kidney cells (HEK-293) were obtained from the Beijing Beina Chuanglian Biotechnology Research Institute (Beijing, China). Human gastric cancer cells (HGC-27) were obtained from Dalian Meilun Biotechnology Co., Ltd. (Dalian, China). PC-3M, A549, and BEL-7402 cells were cultured in 1640 medium supplemented with 10% fetal bovine serum and 1% penicillin-streptomycin. HGC-27 and HEK-293 cells were cultured in DMEM medium containing the same components. All media and reagents were purchased from Thermo Fisher Scientific (Waltham, MA, USA).

4.2.3. Evaluation of Cell Viability Using the MTT Assay

The MTT colorimetric assay was used to evaluate the inhibitory effects of WO and its derivatives on tumor cells. The cells were seeded into 96-well plates and cultured until they were fully confluent. They were then incubated in a medium containing the compounds for 48 h. Serum-free medium containing MTT was then added for further incubation. The MTT crystals were dissolved in DMSO, and the optical density (OD) value at 490 nm was measured. The inhibition rate was calculated as follows: (OD value of treated wells/OD value of control wells) × 100. The IC50 was calculated by plotting a curve of treatment concentration versus inhibition rate.

4.2.4. High-Performance Liquid Chromatography (HPLC) Detection of WO and Mito-WO-8 Aggregation in Mitochondria

Please refer to this literature for specific experimental procedures [34]: PC-3M cells were cultured and seeded into two 100 mm culture dishes. Once the cells had adhered to and covered the bottom of the dishes, the derivative and wogonin were diluted to a final concentration of 10 μmol/L. After seven hours of drug treatment, the cells were trypsinized, centrifuged, and the supernatant was discarded. The cells were then resuspended in mitochondrial isolation reagent, iced for 15 min, homogenized using a cell homogenizer, and centrifuged at 600× g for 10 min at 4 °C. The supernatant was collected. This was then further centrifuged at 11,000× g for 10 min at 4 °C, and the supernatant was discarded to obtain the mitochondria. Resuspend in 200 μL PBS. Extract the lower organic phase with an equal volume of dichloromethane using ultrasonication. Repeat the extraction process twice, combine the organic phases, evaporate them to dryness, and then dissolve each one in 120 μL of a solution containing 0.1% formic acid and methanol. Take 20 μL for high-performance liquid chromatography (HPLC) analysis. The chromatography conditions were as follows: methanol/0.1% formic acid aqueous solution (80:20); flow rate, 1 mL/min; detection wavelength, 270 nm.

4.2.5. Detection of Relevant Indicators

Detection of ROS levels: Following digestion, PC-3M cells were seeded into 6-well plates at a density of 2.5 × 105 cells/mL, with 2 mL of solution added to each well. The cultures were then incubated overnight at 37 °C in a 5% CO2 incubator. Add drugs at different concentrations (1.25, 2.5, and 5 μmol/L) to treat the cells. Establish a negative control group (blank control) and a positive control group (ROS up group) simultaneously. Incubate for 48 h. After the drug treatment period, add 10 μmol/L DCFH-DA and incubate for 30 min. After the DCFH-DA incubation period, the cells were digested and centrifuged, and the supernatant was discarded. The cells were then resuspended in PBS to form a cell suspension and analyzed immediately by fluorescence cytometry.
JC-1 Membrane Potential Assay: Seed PC-3M cells into a 6-well plate at a density of 2.5 × 105 cells/mL, adding 2 mL of cells to each well. Incubate overnight at 37 °C with 5% CO2. Treat the cells with different concentrations of the drug (1.25, 2.5, and 5 μmol/L), and include a blank control group. Incubate for 48 h. After the drug exposure period, add a 5 μg/mL working solution of JC-1 and incubate for 30 min. Following JC-1 incubation, remove the dye and wash three times with PBS. Observe under an inverted fluorescence microscope.
Assaying MPTP permeability in membranes: Seed PC-3M cells into a 6-well plate at a density of 2.5 × 105 cells/mL, adding 2 mL of cells to each well. Incubate overnight at 37 °C with 5% CO2. Treat the cells with different concentrations of the drug (1.25, 2.5, and 5 μmol/L), and include a blank control group. Incubate for 12 h. Wash twice with phosphate-buffered saline (PBS). Add 500 µL of Calcein AM staining solution (containing 2 µM Calcein AM and 5 mM CoCl2) to each well. Incubate at 37 °C in the dark for 30 min. Discard the staining solution and wash three times with PBS. Observe under an inverted fluorescence microscope.

4.2.6. Apoptosis Analysis

DAPI staining: Collect log-phase PC-3M cells and prepare a cell suspension at a concentration of 1.5 × 105 cells/mL. Seed the cells at a density of 1 mL per well in a 12-well plate. After 24 h of culture, treat the cells with different concentrations of drugs (1.25, 2.5, and 5 μmol/L) and include a control group. After 48 h of incubation, the cells were washed twice with PBS. Add 4% tissue cell fixative to each well and leave to fix at room temperature for 15 min. Wash twice with PBS. Add 500 μL of DAPI staining solution to each well. Incubate at 37 °C in the dark for 20 min, then observe under an inverted fluorescence microscope.
Annexin V-FITC/PI dual staining was performed to detect apoptosis: Log-phase PC-3M cells were collected, trypsinized for 1.5 min, counted, and seeded into 6-well plates at a final concentration of 2 × 105 cells/mL. After 24 h, the cells were treated with different concentrations of the drug (1.25, 2.5, and 5 μmol/L), with a control group. After 48 h, the cell culture medium was transferred to centrifuge tubes. The cells were digested with EDTA-free trypsin, centrifuged, and the supernatant discarded. The cells were then resuspended in 1 mL of ice-cold PBS, centrifuged again, and the supernatant discarded. The cells were then resuspended in binding buffer (1×) to a concentration of 1 × 106 cells/mL. Transfer 100 μL of the cell suspension to a flow cytometry tube and add 5 μL of Annexin V-FITC solution. Mix thoroughly. Incubate at room temperature in the dark for 5 min, then add 5 μL of propidium iodide (PI) solution and 400 μL of PBS before analyzing on the flow cytometer.

4.2.7. Transcriptome Analysis

PC-3M cells were cultured and divided into two groups: a blank group (N) and a control group (W8T, 10 μmol/L Mito-WO-8). After treatment, total RNA was extracted from the cells. The samples were rapidly frozen in liquid nitrogen, stored on dry ice, and sent to Sangon Biotech Co., Ltd. (Shanghai, China). for cDNA library construction and sequencing. The workflow included the following steps: Total RNA extraction; mRNA enrichment; mRNA fragmentation; cDNA reverse transcription; DNA sequencing adapter ligation; PCR amplification of the library; Deep sequencing.

4.2.8. Network Pharmacology Analysis

Data on human prostate cancer cells and normal human prostate cells were collected from the TCGA database (dataset ID: TCGA-BLCA). Differential analysis was performed using the “DESeq2” package to obtain fold change (FC) values and adjusted p-values for each gene. Genes that were significantly differentially expressed between human prostate cancer cells and normal prostate cells were identified by setting a threshold of |log2 FC| > 1.5 and p < 0.05. Human mitochondrial-related gene data were collected from the Mito Carta 3.0 database (https://www.broadinstitute.org/mitocarta, accessed on 27 February 2025). After correction, target genes from each database were merged and deduplicated. Venn diagram mapping was performed to identify intersection targets between the differentially expressed genes and the mitochondrial genes.
To ensure accurate docking, the target protein and compounds (WO and Mito-WO-8) were prepared using AutoDock Vina (1.5.7) and AutoDock Tools, including hydrogenation, Gasteiger charging, and merging nonpolar hydrogens. The protein was designated as the receptor, and WO and Mito-WO-8 as ligands. Original PDB files were converted to PDBQT format for docking. Finally, protein–ligand interactions were visualized using PyMOL (4.60).

4.2.9. RT-qPCR Experiment

PC-3M cells were cultured and divided into two groups: a blank control group and a Mito-WO-8 (10 μmol/L) treatment group. Following treatment, total RNA was extracted from the cells. The samples were rapidly frozen in liquid nitrogen, stored in dry ice, and sent to Sangon Biotech (Shanghai) Co., Ltd., for primer design. RT-qPCR was performed to detect mRNA expression of GPD2, MKK6, p38, and DDIT3.Primer sequences are listed in Table S1.

4.2.10. Western Blot Assay

Collect the drug-treated culture medium, including both adherent and suspension cells, into centrifuge tubes. Determine the protein concentration using the BCA method. Select an SDS-PAGE gel system with an appropriate concentration based on the molecular weight of the target protein for electrophoresis. After electrophoresis, perform membrane transfer on the processed samples. Incubate the membrane overnight at 4 °C in the corresponding primary antibody dilution buffer following transfer. Retrieve the bands that bind to the primary antibody, then incubate them with a species-specific secondary antibody for one hour. Prior to exposure, add ECL chemiluminescent solution. After exposure, obtain the Western blot protein bands. All protein band intensities were normalized to the corresponding β-actin band intensity for each sample. Densitometric analysis was performed in ImageJ (version 1.53t) using three independent biological replicates (n = 3). Data are presented as means ± standard deviation (SD), and statistical significance was determined using one-way analysis of variance (ANOVA) followed by Bonferroni’s multiple-comparison test.

4.2.11. Statistical Analysis

All experiments were performed in three independent biological replicates, each containing triplicate technical measurements, unless otherwise specified. Data are presented as mean ± standard deviation (SD). All statistical analyses were performed using GraphPad Prism (version 6; San Diego, CA, USA). Group comparisons were analyzed using one-way analysis of variance (ANOVA) followed by Bonferroni’s multiple-comparison test. A probability level of p < 0.05 was considered statistically significant for all analyses.

5. Conclusions

This study reports on the synthesis of 27 compounds, nine of which are novel mitochondrial-targeted wogonin derivatives. Mito-WO-8, one of these compounds, exhibited significant cytotoxicity against PC-3M cells. Mito-WO-8 accumulates in tumor cell mitochondria, inducing reactive oxygen species (ROS) production, reducing mitochondrial membrane potential, and promoting mitochondrial pore opening. These effects indicate impaired mitochondrial function and are associated with the activation of the p38/MAPK signaling pathway and subsequent caspase-3 release. Ultimately, this leads to apoptosis in PC-3M cells. Suppression of GPD2 protein expression was also observed during this process. However, further experimental validation is needed to confirm the correlation between this finding and the observed apoptotic effects.

Supplementary Materials

The following supporting information can be downloaded at https://www.mdpi.com/article/10.3390/molecules31050859/s1, Table S1: RT-qPCR primer sequences (https://static.pubmed.gov/portal/portal.fcgi/, accessed on 5 March 2025); Cell doubling curve, Spectral information of compounds; Molecular docking and molecular dynamics (https://www.uniprot.org/, accessed on 17 March 2025); Mass spectrometry data and HPLC chromatogram of Mito-WO-8; Abbreviations List.

Author Contributions

Conceptualization, D.L., J.H. and E.C.; methodology, W.L. and Y.Z.; software, F.L. and M.S.; validation, D.L., F.L., M.S. and F.S.; formal analysis, D.L.; investigation, F.L.; writing—original draft preparation, D.L. and F.L.; writing—review and editing, J.H. and E.C.; visualization, J.H.; supervision, E.C.; project administration, E.C.; funding acquisition, J.H. All authors have read and agreed to the published version of the manuscript.

Funding

This research was funded by the Project of the Natural Science Foundation of Jilin Province (project No. 20260102117JC).

Institutional Review Board Statement

Not applicable.

Data Availability Statement

The data that support the findings of this study are available from the corresponding author upon reasonable request.

Conflicts of Interest

The authors declare no conflicts of interest.

References

  1. Sung, H.; Ferlay, J.; Siegel, R.L.; Laversanne, M.; Soerjomataram, I.; Jemal, A.; Bray, F. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J. Clin. 2021, 71, 209–249. [Google Scholar] [CrossRef] [Scilit]
  2. Ji, Y.; Li, S.; Zhang, X.; Liu, Y.; Lu, Q.; Li, Q.; Chen, W.; Sheng, J.; Jiang, K.; Liang, H.; et al. The prophylactic and therapeutic effects of moxibustion combined with traditional Chinese medicine decoction for treating chemotherapy-induced myelosuppression in early-stage breast cancer: Study protocol for a randomized controlled trial. Trials 2020, 21, 844. [Google Scholar] [CrossRef] [Scilit]
  3. Rapoport, B.L.; Cooksley, T.; Johnson, D.B.; Anderson, R.; Shannon, V.R. Treatment of infections in cancer patients: An update from the neutropenia, infection and myelosuppression study group of the Multinational Association for Supportive Care in Cancer (MASCC). Expert Rev. Clin. Pharmacol. 2021, 14, 295–313. [Google Scholar] [CrossRef] [Scilit]
  4. Guan, W.; Qi, W. Ginsenoside Rh2: A shining and potential natural product in the treatment of human nonmalignant and malignant diseases in the near future. Phytomedicine Int. J. Phytother. Phytopharm. 2023, 118, 154938. [Google Scholar] [CrossRef] [Scilit]
  5. Newman, D.J.; Cragg, G.M. Natural Products as Sources of New Drugs over the Nearly Four Decades from 01/1981 to 09/2019. J. Nat. Prod. 2020, 83, 770–803. [Google Scholar] [CrossRef] [Scilit]
  6. Zhang, B.B.; Wang, D.G.; Guo, F.F.; Xuan, C. Mitochondrial membrane potential and reactive oxygen species in cancer stem cells. Fam. Cancer 2015, 14, 19–23. [Google Scholar] [CrossRef] [Scilit]
  7. Burke, P.J. Mitochondria, Bioenergetics and Apoptosis in Cancer. Trends Cancer 2017, 3, 857–870. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  8. Luis-García, E.R.; Becerril, C.; Salgado-Aguayo, A.; Aparicio-Trejo, O.E.; Romero, Y.; Flores-Soto, E.; Mendoza-Milla, C.; Montaño, M.; Chagoya, V.; Pedraza-Chaverri, J.; et al. Mitochondrial Dysfunction and Alterations in Mitochondrial Permeability Transition Pore (mPTP) Contribute to Apoptosis Resistance in Idiopathic Pulmonary Fibrosis Fibroblasts. Int. J. Mol. Sci. 2021, 22, 7870. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  9. Jiang, X.P.; Jin, S.; Shao, W.; Zhu, L.; Yan, S.; Lu, J. Saponins of Marsdenia Tenacissima promotes apoptosis of hepatocellular carcinoma cells through damaging mitochondria then activating cytochrome C/Caspase-9/Caspase-3 pathway. J. Cancer 2022, 13, 2855–2862. [Google Scholar] [CrossRef] [Scilit]
  10. Yang, Y.; Karakhanova, S.; Hartwig, W.; D’Haese, J.G.; Philippov, P.P.; Werner, J.; Bazhin, A.V. Mitochondria and Mitochondrial ROS in Cancer: Novel Targets for Anticancer Therapy. J. Cell. Physiol. 2016, 231, 2570–2581. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  11. Zeng, Z.; Fang, C.; Zhang, Y.; Chen, C.X.; Zhang, Y.F.; Zhang, K. Mitochondria-Targeted Nanocarriers Promote Highly Efficient Cancer Therapy: A Review. Front. Bioeng. Biotechnol. 2021, 9, 784602. [Google Scholar] [CrossRef] [Scilit]
  12. Gianpiero, C.; Anis, D.; Aikaterini, R.; Eirini, T.; Ioannis, V.S.; Dimitrios, F.G.; John, T. Boron-containing delocalised lipophilic cations for the selective targeting of cancer cells. MedChemComm 2017, 8, 67–72. [Google Scholar] [CrossRef] [Scilit]
  13. Siebert, V.; Silber, M.; Heuten, E.; Muhle-Goll, C.; Lemberg, M.K. Cleavage of mitochondrial homeostasis regulator PGAM5 by the intramembrane protease PARL is governed by transmembrane helix dynamics and oligomeric state. J. Biol. Chem. 2022, 298, 102321. [Google Scholar] [CrossRef] [Scilit]
  14. Ma, L.; Wang, X.; Li, W.; Li, T.; Xiao, S.; Lu, J.; Xu, J.; Zhao, Y. Rational design, synthesis and biological evaluation of triphenylphosphonium-ginsenoside conjugates as mitochondria-targeting anti-cancer agents. Bioorg. Chem. 2020, 103, 104150. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  15. Ju, W.; Li, N.; Wang, J.; Yu, N.; Lei, Z.; Zhang, L.; Sun, J.; Chen, L. Design and synthesis of novel mitochondria-targeted CDDO derivatives as potential anti-cancer agents. Bioorg. Chem. 2021, 115, 105249. [Google Scholar] [CrossRef] [Scilit]
  16. Zhao, Y.; Zhang, L.; Wu, Y.; Dai, Q.; Zhou, Y.; Li, Z.; Yang, L.; Guo, Q.; Lu, N. Selective anti-tumor activity of wogonin targeting the Warburg effect through stablizing p53. Pharmacol. Res. 2018, 135, 49–59. [Google Scholar] [CrossRef] [Scilit]
  17. Dandawate, S.; Williams, L.; Joshee, N.; Rimando, A.M.; Mittal, S.; Thakur, A.; Lum, L.G.; Parajuli, P. Scutellaria extract and wogonin inhibit tumor-mediated induction of T(reg) cells via inhibition of TGF-β1 activity. Cancer Immunol. Immunother. 2012, 61, 701–711. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  18. Huang, K.F.; Zhang, G.D.; Huang, Y.Q.; Diao, Y. Wogonin induces apoptosis and down-regulates survivin in human breast cancer MCF-7 cells by modulating PI3K-AKT pathway. Int. Immunopharmacol. 2012, 12, 334–341. [Google Scholar] [CrossRef] [Scilit]
  19. Hong, M.; Almutairi, M.M.; Li, S.; Li, J. Wogonin inhibits cell cycle progression by activating the glycogen synthase kinase-3 beta in hepatocellular carcinoma. Phytomedicine Int. J. Phytother. Phytopharm. 2020, 68, 153174. [Google Scholar] [CrossRef] [Scilit]
  20. Wu, X.; Liu, P.; Zhang, H.; Li, Y.; Salmani, J.M.; Wang, F.; Yang, K.; Fu, R.; Chen, Z.; Chen, B. Wogonin as a targeted therapeutic agent for EBV (+) lymphoma cells involved in LMP1/NF-κB/miR-155/PU.1 pathway. BMC Cancer 2017, 17, 147. [Google Scholar] [CrossRef] [Scilit]
  21. Li, L.; Lu, N.; Dai, Q.; Wei, L.; Zhao, Q.; Li, Z.; He, Q.; Dai, Y.; Guo, Q. GL-V9, a newly synthetic flavonoid derivative, induces mitochondrial-mediated apoptosis and G2/M cell cycle arrest in human hepatocellular carcinoma HepG2 cells. Eur. J. Pharmacol. 2011, 670, 13–21. [Google Scholar] [CrossRef] [Scilit]
  22. Zhang, L.; Qiang, L.; Chen, F.; Wu, T.; Rong, J.; Zhao, Q.; Zou, M.; Yang, Z.; You, Q.; Li, Z.; et al. DHF-18, a new synthetic flavonoid, induced a mitochondrial-mediated apoptosis of hepatocarcinoma cells in vivo and in vitro. Eur. J. Pharmacol. 2011, 651, 33–40. [Google Scholar] [CrossRef] [Scilit]
  23. Yang, C.; Zhu, S.; Chen, Y.; Liu, Z.; Zhang, W.; Zhao, C.; Luo, C.; Deng, H. Flavonoid 4,4′-dimethoxy chalcone suppresses cell proliferation via dehydrogenase inhibition and oxidative stress aggravation. Free. Radic. Biol. Med. 2021, 175, 206–215. [Google Scholar] [CrossRef] [Scilit]
  24. Dewanjee, S.; Chakraborty, P.; Bhattacharya, H.; Singh, S.K.; Dua, K.; Dey, A.; Jha, N.K. Recent advances in flavonoid-based nanocarriers as an emerging drug delivery approach for cancer chemotherapy. Drug Discov. Today 2023, 28, 103409. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  25. Liu, X.; Zhang, J.; Liu, L.; Jiang, Y.; Ji, J.; Yan, R.; Zhu, Z.; Yu, Y. Protein arginine methyltransferase 5-mediated epigenetic silencing of IRX1 contributes to tumorigenicity and metastasis of gastric cancer. Biochim. Biophys. Acta Mol. Basis Dis. 2018, 1864, 2835–2844. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  26. Sethi, G.; Sung, B.; Aggarwal, B.B. TNF: A master switch for inflammation to cancer. Front. Biosci. 2008, 13, 5094–5107. [Google Scholar] [CrossRef] [Scilit]
  27. Fulda, S.; Galluzzi, L.; Kroemer, G. Targeting mitochondria for cancer therapy. Nat. Rev. Drug Discov. 2010, 9, 447–464. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  28. Murphy, M.P. Targeting lipophilic cations to mitochondria. Biochim. Biophys. Acta 2008, 1777, 1028–1031. [Google Scholar] [CrossRef] [Scilit]
  29. Weinberg, S.E.; Chandel, N.S. Targeting mitochondria metabolism for cancer therapy. Nat. Chem. Biol. 2014, 11, 9–15. [Google Scholar] [CrossRef] [Scilit]
  30. Yi, C.; Feng, W.; Zhang, G.; Luo, J.; Chen, Y.; Feng, Q.; Zhu, Y.; Guo, Y.; Yan, X.; Ma, M. Cinnamaldehyde suppresses ovarian cancer progression by activating ROS-mediated apoptosis and mitophagy. Biochem. Pharmacol. 2025, 244, 117604. [Google Scholar] [CrossRef] [Scilit]
  31. Poulos, R.C.; Hains, P.G.; Shah, R.; Lucas, N.; Xavier, D.; Manda, S.S.; Anees, A.; Koh, J.M.S.; Mahboob, S.; Wittman, M.; et al. Strategies to enable large-scale proteomics for reproducible research. Nat. Commun. 2020, 11, 3793. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  32. Klingenberg, M. Localization of the glycerol-phosphate dehydrogenase in the outer phase of the mitochondrial inner membrane. Eur. J. Biochem. 1970, 13, 247–252. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  33. Lin, C.-H.; Jiang, W.-P.; Itokazu, N.; Huang, G.-J. Chlorogenic acid attenuates 5-fluorouracil-induced intestinal mucositis in mice through SIRT1 signaling-mediated oxidative stress and inflammatory pathways. Biomed. Pharmacother. 2025, 186, 117982. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  34. Song, H.; Xing, W.; Shi, X.; Zhang, T.; Lou, H.; Fan, P. Antitumor and toxicity study of mitochondria-targeted triptolide derivatives using triphenylphosphine (TPP+) as a carrier. Bioorg. Med. Chem. 2021, 50, 116466. [Google Scholar] [CrossRef] [Scilit] [PubMed]
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Article Metrics

Citations

Article Access Statistics

Multiple requests from the same IP address are counted as one view.